Koios DS Breast™ AI Available on GE Healthcare’s Automated Breast Ultrasound to Support Early Breast Cancer Detection

Koios Medical and GE Healthcare join forces again in early breast cancer detection making Koios DS Breast AI software available on the Invenia 2.0 ABUS system.

GE Healthcare (NYSE:GE)

GE Healthcare is dedicated to being at the forefront of innovation in breast ultrasound and our collaboration with Koios Medical is another great milestone building upon that commitment…”

— Brian McEathron, Vice President, General Imaging at GE Healthcare

NEW YORK, NEW YORK, USA, September 16, 2021 /EINPresswire.com/ — Koios Medical, a developer of artificial intelligence (AI) for early cancer detection and diagnostic accuracy, announced a strategic partnership with GE Healthcare with the launch of the company’s AI software available on GE’s InveniaTM ABUS 2.0 automated whole breast ultrasound scanning system, the only FDA-approved ultrasound supplemental breast screening technology specifically designed for detecting cancer in dense breast tissue.

Koios DS Breast is the only FDA-cleared cancer diagnosis software using AI on breast ultrasound images that works as an on-demand second opinion. The powerful combination gives Invenia ABUS users access to Koios DS AI algorithms trained for ultrasound image interpretation and assessment streamlining clinical workflow while improving clinical accuracy and patient care.

One out of every eight women in the US is expected to contract breast cancer over the course of her lifetime making breast cancer the leading cancer diagnosis in women worldwide. That risk is even greater for the more than 40 percent of women with dense breast tissue that requires automated or traditional ultrasound (or MRI) as a supplement to routine mammograms. Earliest possible detection is critical to increased survival rates while mitigating treatment complexity. Use of AI software in conjunction with ultrasound dramatically expands access to quality care and early diagnosis.
Koios DS BreastTM decision support software is approved and commercially available in the US and internationally integrated within GE’s LOGIQTM E10 Series and LOGIQ P-Series ultrasound system and GE CentricityTM PACS making the addition to the Invenia ABUS 2.0 system an extension of the power of AI broadly across GE’s ultrasound offering.

“Joining forces with the GE ABUS team and the Invenia ABUS 2.0 system now gives patients and physicians the speed, accuracy and peace of mind only made possible by combining AI with whole breast ultrasound. This combination is extremely inspiring. To know patients will experience fewer missed cancers and less avoidable procedures not to mention eliminating the anxiety imposed on women and their families from the millions of ‘false alarms’ every year motivates the Koios Medical team to continue innovating and integrating” says Koios Medical’s CEO Chad McClennan.

Advantages of this powerful combination include rapid and accurate diagnostic performance improving cancer detection rates, especially on women with dense breast tissue. Koios DS Breast, or Smart Ultrasound™, used in conjunction with Invenia ABUS 2.0 simultaneously reduces false positive interpretations resulting in fewer patient callbacks, less benign biopsy procedures and relieving patient stress while mitigating costly out of pocket expenses.

Koios DS Breast AI software was trained on nearly one million ultrasound images of both malignant and benign breast lesions from sources around the world to improve physician diagnostic accuracy. The system generates a likelihood of malignancy finding aligned to both the American College of Radiology’s BI-RADS rating schema and the European rating systems.

“GE Healthcare is dedicated to being at the forefront of innovation in breast ultrasound and our collaboration with Koios Medical is another great milestone building upon that commitment. This is one of the most advanced clinical decision support tools available to clinicians worldwide to assist and ultimately improve cancer detection within a streamlined workflow and by offering this on both our LOGIQ and Invenia ABUS ultrasound systems, we aim to improve outcomes for clinicians and their patients,” said Brian McEathron, Vice President, General Imaging Ultrasound at GE Healthcare.
Koios is a partner in GE Healthcare’s Edison Developer Program, a dynamic ecosystem which helps innovators deliver advanced healthcare applications, integrate products, and drive commercial growth. Designed for its Edison platform, the program offers services to help developers build better models for clinical, operational or financial improvements. Applications developed using Edison can be quickly and securely deployed in the cloud, on premise (e.g.,via GE Healthcare’s Edison HealthLink appliance), or directly onto smart imaging devices.

“Koios Medical will continue building on our initial success combining AI with ultrasound. Invenia ABUS 2.0 enables a reduction in image acquisition variability while the Koios Smart Ultrasound AI software augments performance further by reducing physician interpretation variability, increasing overall accuracy and speed. Now with a new CPT category 3 billing code effective this January, ultrasound, as a modality, is poised to dramatically expand adoption and clinical impact with the power of this new combination of AI with the Invenia ABUS 2.0 system.” says Koios Medical CEO Chad McClennan.

The GE Invenia 2.0 ABUS system is currently deployed at hundreds of facilities around the world and the Koios DS Breast “Smart Ultrasound” software has already been activated in dozens of practices and healthcare institutions across the US, Middle East, Europe, and South America since expanding internationally early in 2021.

About Koios Medical:
Koios Medical (www.koiosmedical.com) develops medical software to assist physicians interpreting ultrasound images and applies deep machine learning methods to the process of reaching an accurate diagnosis. The Koios DS platform uses advanced AI algorithms to assist in the early detection of disease while reducing recommendations for biopsy of benign tissue. Patented technology saves physicians time, helps improve patient outcomes, and reduces healthcare costs. Koios DS (decision support) is presently focused on the breast and thyroid cancer diagnosis market. Women with dense breast tissue (over 40% in the US) often require an alternative to mammography for diagnosis. Ultrasound is a widely available and effective alternative to mammography using no ionizing radiation and is a standard of care for breast cancer diagnosis. To learn more please contact us at info@koiosmedical.com or (732) 529-5755.

About GE Healthcare:
GE Healthcare is the $19 billion healthcare business of GE (NYSE: GE). As a leading provider of medical imaging, monitoring, biomanufacturing, and cell and gene therapy technologies, GE Healthcare enables precision health in diagnostics, therapeutics and monitoring through intelligent devices, data analytics, applications, and services. With over 100 years of experience in the healthcare industry and more than 50,000 employees globally, the company helps improve outcomes more efficiently for patients, healthcare providers, researchers, and life sciences companies around the world. Follow us on Facebook, LinkedIn, Twitter, and The Pulse for latest news, or visit our website www.gehealthcare.com for more information.

Tonja Haugh
Koios Medical
+1 716-574-2165
email us here

Koios DS SmartClick

Source: EIN Presswire

Analytical science leaders honored at the 2021 AOAC INTERNATIONAL Annual Meeting


At the 2021 AOAC Annual Meeting in Boston, MA, an awards ceremony honored hundreds of scientists for their contributions to AOAC and scientific excellence.

This year’s award winners represent the analytical excellence that makes AOAC the highly respected organization we strive for.”

— Erin Crowley, AOAC President

ROCKVILLE, MD, USA, September 16, 2021 /EINPresswire.com/ — At the 2021 AOAC INTERNATIONAL Annual Meeting in Boston, MA, an awards ceremony honored hundreds of analytical science leaders for their contributions to AOAC and scientific excellence. Twenty-one awards recognized scientific excellence across the spectrum of AOAC activities, including method development, expert review panels, editorial contributions to the Journal of AOAC INTERNATIONAL, and technical service.

“This year’s award winners represent the analytical excellence that makes AOAC the highly respected organization we strive for,” said AOAC President Erin Crowley. “From Dr. DeVries and his 40 years of dedication to our student winners just beginning their journeys, we are grateful for their passion and contributions to food safety and public health.”

The Harvey W. Wiley Award, AOAC’s most prestigious scientific award presented for outstanding contributions to analytical method development in an area of interest to AOAC, was awarded to Katerina Mastovska. Dr. Mastovska is a Chief Scientific Officer at Eurofins US Food Division and a Technical & Industrial Director for Pesticides within the Operational Best Practices Program at Eurofins Scientific. An AOAC member since 2004, she has chaired or contributed to more than 20 AOAC expert review panels (ERPs), working groups, and stakeholder panels and has collaborated on or authored five AOAC Official Methods of Analysis℠.

As part of the Harvey W. Wiley Award program, the winner can nominate a student to receive the Harvey Wiley Award Scholarship. This year’s winner was Katerina Sebelova of the University of Chemistry and Technology, Prague. Her PhD work focuses on plant alkaloids in natural products and foodstuffs, as well as metabolomic and lipidomic of edible insects using advanced techniques.

The William Horwitz Award, the highest volunteer award bestowed by AOAC, went to Jonathan W. DeVries, Sr., who has served the Association for over four decades in both scientific and leadership roles. A consultant in foods, nutrition, and chemistry at DeVries and Associates, he brings more than 50 years of experience in quality-related analytical work, with more than 40 years in nutrition and food safety analysis and research. DeVries is only the third recipient of this prestigious award in AOAC’s history.

The Fellow of AOAC INTERNATIONAL Award, which recognizes the dedication of the volunteers who serve the Association, was awarded to seven highly dedicated members of the food safety community: Sean Austin of Nestle Research; Yi Chen of the FDA and CFSAN; Thierry Delatour of Nestec Ltd; Cheng-Zhu Liang of Qingdao Customs; Alfredo Montes-Nino of Microbiotics; Franz Ulberth of the European Commission; and Sudhakar Yadlapalli of First Source Laboratory.

Three student awards, two new and one in its second year, were awarded.

The first AOAC INTERNATIONAL/Herbalife Nutrition Scholarship, supported by contributions from Herbalife Nutrition and designed to encourage student researchers who are advancing analytical or molecular (DNA) testing in herbal or dietary supplements, was awarded to Brittany McIntyre of the University of Guelph and Jakub Tomasko of the University of Chemistry and Technology, Prague.

The first AOAC INTERNATIONAL/SCIEX Rising Star Award, supported by contributions from SCIEX and designed to encourage the integration of graduate students into AOAC who offer demonstrable potential to become thought leaders and scientific influencers in their respective fields, was awarded to Klara Navratilova of the University of Chemistry and Technology, Prague.

The second annual AOAC INTERNATIONAL/Eurofins Foundation “Testing for Life” Student Award, supported by contributions from the Eurofins Foundation, is designed to encourage student researchers who are advancing basic or applied science in analytical or molecular testing for food safety, security, defense, or authenticity, or health and environmental protection. This year’s award went to five students: Maryam Abdur-Rahman of the University of Maryland, Baltimore County; Tengfei Li of the University of Nebraska-Lincoln; Xingchen Liu of the University of Maryland; Raviraj Shinde of Shivaji University; and Leos Uttl of the University of Chemistry and Technology, Prague.

The Paper of the Year, recognizing the most outstanding original and creative journal article published in the peer-reviewed Journal of AOAC INTERNATIONAL, went to Yuecheng Zhang of Malmö University for his article, “A Green, Economic “Switch-On” Sensor for Cefixime Analysis Based on Black Soya Bean Carbon Quantum Dots”.

The Section of the Year Award recognized the AOAC India Section for its collaboration with the Food Safety and Standards Authority of India (FSSAI), efforts to engage with potential new partners to increase membership in the region and promote recognition of AOAC, and involvement of its young scientists and a new online platform.

The AOAC Official Methods Board (OMB) presented four awards this year, recognizing significant contributions and meritorious volunteer service to the AOAC analytical scientific community.

The Technical Service Award went to Dustin Starkey of Abbott Nutrition and Robert LaBudde of Least Cost Formulations, Ltd for their dedication to AOAC analytical and technical communities in their areas of expertise. Starkey has contributed extensively to AOAC’s Stakeholder Program on Infant Formula and Adult Nutritionals and Food Authenticity Methods Program, and LaBudde is a longtime volunteer and member of the AOAC Committee on Statistics.

The Award in Recognition of Technical and Scientific Excellence was presented to AOAC’s COVID-19 Emergency Response Validation Program Advisory Group for their efforts to evaluate test kits for detection of the SARS-CoV-2 virus on stainless steel surfaces during the height of the global COVID-19 pandemic.

The Expert Review Panel (ERP) of the Year went to the Cannabis Analytical Science Program (CASP) ERP for Cannabinoids, chaired by Melissa Phillips of the National Institute of Standards and Technology, who reviewed methods for cannabinoids in cannabis to ensure they met AOAC CASP standards in support of requirements in the USDA Final Rule for testing hemp.

The final OMB award, the Method of the Year, went to “Quantitation of Cannabinoids in Cannabis Dried Plant Materials, Concentrates, and Oils Using Liquid Chromatography–Diode Array Detection Technique with Optional Mass Spectrometric Detection: Single-Laboratory Validation Study, First Action 2018.11.” Nine authors contributed to this method.

In addition, 234 AOAC members were recognized for their continuous years of service: two 50-year members, two 45-year members, nine 40-year members, seven 35-year members, twelve 30-year members, eleven 25-year members, 58 ten-year members, and 133 five-year members.

Katie Bergmann
+1 240-801-8657
email us here
Visit us on social media:

Source: EIN Presswire

MealBetix.com Launches The MealBetix Lifestyle – the Only 100% Organic Lifestyle

Holistic Lifestyle | Holistic Diet | Holistic Lifestyle Plan

Now is the time to start eating the last real food on earth, before it’s gone.

Holistic Lifestyle | Holistic Diet | Holistic Lifestyle Plan

For Busy Lives! The Only 100% Organic Meal You Can Eat On The Go!

Holistic Lifestyle | Holistic Diet | Holistic Lifestyle Plan

The Last Real Food On Earth Grown In The Last 100% Organic Soil

There Are Thousands Of Diets And Lifestyles Out There But None Can Provide A True Source Of 100% Organic Food Every Day Like The MealBetix Lifestyle

We desperately need a truly clean source of real food that can help keep us healthy every day, before it’s gone forever. And this is what The MealBetix Lifestyle represents.”

— Dr Darren Wayne, aka The Food Guru.

SHERIDAN, WYOMING, UNITED STATES, September 16, 2021 /EINPresswire.com/ — MealBetix.com is a Holistic Lifestyle Company that is home to The MealBetix Lifestyle, which focuses on eating 100% Organic every day.

Founded in late 2020 by Food Scientist, Dr. Darren Wayne, aka The Food Guru, The MealBetix Lifestyle is the ultimate clean food lifestyle and therefore perfect for anyone wanting to improve their health without having to diet.

The MealBetix Lifestyle focuses solely on eating food that was grown in the last 100% Organic soil left here, in other words, is 100% clean, free from all pesticides, herbicides, artificial fertilizers and of course GMOs.

“After spending years searching for any soil that wasn’t contaminated, I finally found it, but just a little bit, and this is where The MealBetix Lifestyle was born.”

Pollution has contaminated everything around us, especially the soil, so just to find a little bit of soil left here that is still clean and pure, had been a very long and extremely arduous task to say the least.

We all desperately need foods with high fiber for constipation, foods with natural fiber and of course vegetables with high fiber low carb, which most everyone needs today, especially those who eat fast food and even those who think they cannot afford to eat 100% Organic every day.

Since The MealBetix Lifestyle was launched, already thousands of people started experiencing more health than they ever have before, saving each person $300 or more on their monthly food bill even, plus saving them money on all their nutrition, too. (https://MealBetix.com)

What this means is that The MealBetix Lifestyle not only provides very rare 100% Organic Food that is of course 100% GMO-free, but costs less than junk food. It’s hard to believe a 100% Organic lifestyle this healthy could ever cost so little, but The Food Guru does not let food corruption raise the cost of 100% Organic food, so everyone, no matter the income and no matter the location, The MealBetix Lifestyle can save you a lot of time, save you a lot of money and especially improve your health.

And The MealBetix Lifestyle just launched the wholesale price, so you can now pay less than junk food to start The MealBetix Lifestyle. Imagine saving enough time each week not having to prepare and cook meals so you can start a hobby, and saving enough money on your food bill every month and save enough on your nutrition each year to take an island vacation. Plus feel your health improving daily! This is nothing short of a miracle, especially these days.

To learn more about The MealBetix Lifestyle, visit https://MealBetix.com

Darren Wayne
+1 626-539-0374
email us here
Visit us on social media:

The Soil Will Be Dead By 2030

Source: EIN Presswire

New Smart Glasses to Be Introduced in the United States This Month by Tokyo-Based Inventor After Success in Japan

HoldOn Ai/ Glasses for kids

Smart glasses Ai glasses logo

Ai Glasses smart glasses logo

Smart glasses for Adults

HoldOn Ai/ Glasses for Adults

Eye care professionals based in the U.S. are needed to test the new HoldOn Ai/Glasses, designed to help prevent nearsightedness and develop eye-friendly habits.

NISHISHINJUKU, SHINJUKU-KU, TOKYO, JAPAN, September 16, 2021 /EINPresswire.com/ — New AI-based eyeglasses that tackle weak eyesight using high-precision sensors will debut in the U.S. at a vision-care trade show this month.

ClearElectron, the Tokyo-based inventor of HoldOn Ai/Glasses, is searching for ophthalmologists, optometrists, and opticians in the U.S. to test the smart glasses, which are already being recommended to patients in Japan.

“Eye care specialists can introduce their patients to the newest technology while also helping to improve their vision, health, and lifestyle,” said Shiken Ono, chief executive officer of ClearElectron.

HoldOn Ai/Glasses use sensors and vibrations to monitor poor posture, note the distance between the wearer and a screen, measure a room’s brightness, and calculate screen time. By alerting wearers to their eye-harming habits, the glasses lower the risk of myopia and vision problems due to the overuse of electronic devices.

The glasses will be introduced to the U.S. market at Vision Expo West from Sept. 23-25 in Las Vegas.

Thomas Tanoue
ClearElectron Co., Ltd.
Visit us on social media:

Ai/Glasses are smart glasses from Tokyo that uses AI to correct bad posture and protect your eyes.

Source: EIN Presswire

Colposcopes Market : Industry Analysis & Opportunities-DataM Intelligence

Research Report

DataM Intelligence

The Global Colposcopes Market is expected to grow at a high CAGR of 6.4% during the forecasting period (2021-2028).

The Global Colposcopes Market is expected to grow at a high CAGR of 6.4% during the forecasting period (2021-2028).”

— DataM Intelligence

CLEVELAND, OHIO, UNITED STATE AMERICA, September 16, 2021 /EINPresswire.com/ —

Market Overview
Colposcopes are the medical instrument used to magnifies the cells of the cervix and vagina. These gadgets are used to diagnose cervical cancer, vaginal cancer, and irritation of the cervix. Colposcopes are made out of an excessive-resolution digicam and electronic green filter for staring at the vagina or cervical cells on the screen.

View full report: https://www.datamintelligence.com/research-report/colposcopes-market

Market Dynamics:
The market is driven by using the rising demand for Colposcopes with the rising prevalence of Cervical Cancer. According to the World Cancer Research Fund Organization, Cervical Cancer is the fourth most usually going on most cancer in women and the eighth most normally taking place most cancers universal global. According to the World Health Organization (WHO), about 570,000 incident cases of Cervical Cancer had been observed internationally in 2018. Around 90% of deaths from Cervical Cancer occurred in low-and center-income countries. Approximately 266,000 ladies died due to Cervical Cancer in 2012.

The upward push inside the approval & release of the novel merchandise shall stimulate the market boom. For instance, in August 2016, CardiacDirect had launched the GT-30 and GT-60 video colposcopes to its growing product portfolio. These colposcopes function the revolutionary R-way Evaluation Program that offers gynecologists a sophisticated exam machine and guidance for cervical ailment prognosis. The GT-30 and GT-60 Video Colposcope characteristic a complete-display screen display that gives a superior degree of accuracy and is prepared with a high-resolution digital camera and a chilly LED lighting fixtures system for zero heat transfer to the affected person.

The marketplace is witnessing technological advancement with the digital platform for the development of colposcopes. For example, in August 2016, MobileODT had received the popularity of the Enhanced Visual Assessment (EVA) System, a cellular cellphone-based connected colposcope. It enables the rural fitness carriers and fitness providers in low-resource settings to enjoy the cost-powerful, net-linked energy of a robust video colposcope. It is a cellular, related, easy-to-use device adopted via an increasing number of businesses running in over 21 countries to strengthen cervical most cancer screening programs' ability and nice. It allows for visualization of the cervix, far-off support of providers with the aid of scientific supervisors, best guarantee and reporting features, affected person follow-up monitoring, and the mixing of records into digital health record structures.

The upward thrust in the businesses, associations, and institutes initiatives for elevating attention concerning Cervical Cancer Prevention and Control shall undoubtedly affect the marketplace. For example, 7 UN corporations underneath the United Nations Task Force on NCDs have undoubtedly impacting Programme to save you and control Cervical Cancer. It aims at providing the prognosis and treatment of invasive cervical most cancers to all ladies, screening, and remedy for cervical pre-most cancers to be had for girls, and Human papillomavirus immunization for girls.

Several agencies, associations, and institutes are moving into a collaboration with the organizations to increase colposcopes. In 2017, Duke University had entered into the collaboration with third Stone Design, Inc to increase a beta prototype of the Pocket Colposcope. It is less high-priced, smaller in size, and lighter than traditional scientific colposcope devices.

However, the excessive value of colposcopes shall hinder the marketplace growth. Moreover, the supply of opportunity techniques for detecting cervical and vaginal cancer, consisting of Pap smear exams and HPV checks, ought to hurt the colposcopes marketplace.

Segment Analysis
By Instrument Type
• Optical Colposcope
• Digital Colposcope
By Instrument Portability
• Stationary
• Handheld
By Application
• Cervical Cancer Screening
• Physical Examinations
• Others
By End-Users
• Hospitals
• Clinics
• Diagnostic centers
• Others

Download free sample: https://www.datamintelligence.com/download-sample/colposcopes-market

Geographical Presentation
By region, the colposcopes market is segmented into North America, South America, Europe, Asia-Pacific, Middle-East, and Africa. Among all of the regions, North America dominated the colposcopes market due to the higher adoption of colposcopes with the increasing prevalence of Cervical Cancer and Vaginal Cancer. According to the Surveillance, Epidemiology, and End Results Program, approximately 13,800 incident Cervical Cancer cases are expected to be observed in 2020 in the United States. Cervical Cancer is the leading cause of cancer death for women in the United States. Around 4,290 women died due to Cervical Cancer in 2020. According to the Centres for Disease Control and Prevention (CDC), around 1,293 women, i.e., 0.6 per 100,000 women, were diagnosed with Vaginal Cancer in 2016. The United States accounts for the highest market share of XX% owing to the high technological advancement, including integrating digital platforms with the colposcopes to stimulate market growth. The ongoing development of colposcopes with high resolution would replace the traditional colposcopes. The North American region is expected to maintain its dominant position over the forecasted period.

The Asia Pacific region is expected to have positive market growth owing to the rising aging population as the older population is at high risk of developing Cervical Cancer. There is a growing penetration of medical imaging technology and improved healthcare facilities, including advanced medical facilities. Several market players are expanding their presence in the Asia Pacific market. Moreover, the rising government spending on gynecological disorders shall boost the demand for colposcopes. Substantial growth is expected to be observed in developing countries owing to the higher incidence rate and mortality rate of Cervical Cancer. The increasing awareness regarding the early diagnosis of Cervical Cancer and Vaginal Cancer shall positively impact the market. For instance, in December 2017, Cancer Institute NSW of Australia, a state-wide positive impacter control agency, had renewed National Cervical Screening Program to reduce the incidence and mortality caused by cervical cancer by organizing screening programs. It involves the primary human papillomavirus (HPV) screening every 5 years for women aged 25–69 years and exit testing for women aged 70–74 years, with partial genotyping for HPV types 16 and 18 and liquid-based cytology triage for other HPV types.

Competitive Analysis
The colposcopes market is highly competitive with the presence of several international and local market players. Product diversification, technological advancement, revenue generation, and opportunities intensify the market competition. Carl Zeiss AG, Olympus Corporation, Danaher Corporation, Cooper Surgical, Inc, McKesson Corporation, DYSIS Medical, and Karl Kaps Gmbh & Co. Kg are the leading Market players with significant market share.

Companies are using novel product launches, technological advancement, new product development, and market expansion strategies for holding their position in the market. For instance, In June 2019, MobileODT had received the 2019 FT/IFC Transformational Business Award in Health, Wellness, and Disease Prevention. In August 2019, MobileODT had received an Innovative Technology contract from Vizient, Inc. for the EVA System, an FDA-cleared smart mobile colposcope for the assessment and diagnosis of cervical cancer and use in forensic examination by Sexual Assault Nurse Examiners.

The companies enter into collaborations, mergers, strategic partnerships, and acquisitions to increase the demand for Colposcopes Market and their expansion across the globe. For instance, in August 2018, Specialty Surgical Instrumentation Inc. (a subsidiary of Symmetry Surgical Inc.) had acquired the Core business segment, i.e., the Electrosurgical segment of Bovie Medical. The Electrosurgical segment includes the generators, electrodes, cauteries, lighting, colposcopes, accessories, and the Bovie brand.

The companies are raising the funding and investment for the development of colposcopes. For instance, in July 2018, DYSIS Medical had completed a $25 million (£18 million) investment to accelerate the growth of its DYSIS Ultra colposcope used in cervical cancer screening. The colposcope uses optical and software techniques to scan a patient’s cervix, quantify the results, and present them to a clinician in the form of an intuitive color-coded map (DYSISmap). The map can be easily shown and explained during an examination, improving understanding and reducing anxiety.

Related Topic's
Endoscopes Market, Resectoscopes Market, Laryngoscopes Market

Sai Kiran
DataM Intelligence 4Market Research LLP
+1 8774414866
Visit us on social media:

Source: EIN Presswire

Kent Imaging Joins Medline Industries as a “Platinum Partner”

Platinum Partnership agreement brings real-time decision-making through non-invasive oxygenation imaging to more wound care specialists.

This partnership helps Medline bring continued innovation and value to our customers, with both companies sharing a passion and vision for helping providers deliver better patient outcomes.”

— AJ Ford, Medline’s VP Sales for Skin Health and Corius

CALGARY, ALBERTA, CANADA, September 16, 2021 /EINPresswire.com/ — Kent Imaging Inc., a leading innovator in oxygenation imaging, announced today that the company has signed a Platinum Partnership agreement with Medline Industries, Inc., a principal manufacturer, and distributor of products dedicated to wound care and limb preservation. The agreement with Medline Industries enables Kent Imaging to expand the reach of their flagship product, SnapshotNIR®, which utilizes near-infrared light to determine tissue oxygen saturation (StO2) in the microvascular network, a key indicator of tissue health. Through the technology, clinicians are better able to plan appropriate interventions, reduce complications and improve outcomes. The initiative, which will see SnapshotNIR added as a key solution within Medline’s client sales and services initiatives, will be initially launched in 10 selected US states.

“We are truly excited to collaborate with such a reputable and impactful organization as Medline Industries in this Platinum Partnership agreement,” says Will Siewert, Kent’s VP Sales (USA). “The synergy delivered through this collaborative effort will support the accelerated adoption of the SnapshotNIR technology, helping clinical specialists in their efforts to reduce complications and improve outcomes.”

“This partnership helps Medline bring continued innovation and value to our customers, with both companies sharing a passion and vision for helping providers deliver better patient outcomes,” explains AJ Ford, Medline’s VP Sales for Skin Health and Corius. “Our technologies are incredibly complementary. The SnapshotNIR device can visually demonstrate positive healing indicators around wound bed preparation and dermal reconstruction using our PluroGel® and Hyalomatrix® technologies, respectively. We very much look forward to introducing SnapshotNIR to leading-edge providers and programs.”

About Kent Imaging, Inc.
Kent Imaging, located in Calgary, Alberta, Canada, is a leading innovator in near-infrared tissue oxygenation imaging, who develops, manufactures, and markets medical technology that supports real-time decision making in wound care, vascular and surgical subspecialties. Kent holds multiple patents in oxygen imaging technology and continues to provide innovative and advanced diagnostic imaging solutions to aid healthcare systems nationally and internationally. For more information about Kent Imaging, visit www.kentimaging.com.

About Medline Industries, Inc.
Medline is a healthcare company: a manufacturer, distributor, and solutions provider focused on improving the overall operating performance of healthcare. Medline works with both the country’s largest healthcare systems and independent facilities across the continuum of care to provide the clinical and supply chain resources required for long-term financial viability in delivering high-quality care. With the size of one of the country’s largest companies and the agility of a family-owned business, Medline is able to invest in its customers for the long term and rapidly respond with customized solutions. Headquartered in Northfield, Ill., Medline has 27,000+ employees worldwide, a fleet of nearly 1,200 trucks, and does business in more than 125 countries. Learn more about Medline at http://www.medline.com/.

Sandra Jenks
Kent Imaging Inc.
+1 4034557610
email us here
Visit us on social media:

Source: EIN Presswire

JADBio AutoML Awarded 1st Prize for Spin-off of the Year, 2021

Ioannis Tsamardinos, CEO at JADBio, receiving the 1st prize for top spin-off in Greece

Ioannis Tsamardinos, CEO at JADBio, receiving the 1st prize for top spin-off in Greece

1st National Startup awards by Elevate Greece

1st National Startup awards by Elevate Greece

JADBio AutoML is changing the field of data analysis worldwide. Our users have already discovered new knowledge about coronavirus and cancer. This award encourages us to step up our efforts.”

— Ioannis Tsamardinos, CEO at JADBio

CALIFORNIA, LOS ANGELES, USA, September 16, 2021 /EINPresswire.com/ — JADBio, a leader in Automated Machine Learning for life-scientists, with offices in Los Angeles(CA), Denmark, and Greece, won the 1st Prize as “Spin-off of the Year”, 2021 at the 1st National Startup Awards by Elevate Greece, the Greek Government's official platform for the Greek Startup Ecosystem. Τhe awards, the brainchild of Christos Dimas, Deputy Minister of Development and Investments, were given out on Saturday, September 11th, at an official event organized during the 85th Thessaloniki International Fair. 250 companies participated in the competition, and 10 of them were awarded. The prime minister of Greece, Kyriakos Mitsotakis, was there along with other ministers, including those from Education, Development, Research, and Innovation. The prize was supported with a 20K euro award from the sponsors, including Eurobank, PRAXI Network, Intel-Lex, and Accenture.

Ioannis Tsamardinos, CEO at JADBio, said, “Special thanks to Elevate Greece and the official sponsors for this important award. JADBio AutoML is changing the field of data analysis worldwide with an emphasis on biomedical and molecular data. Our AI and knowledge intensified application make the construction of predictive models and knowledge discovery, from data, available to everyone. With the use of JADBio, our users have already discovered new knowledge about the coronavirus and cancer. This award encourages us to step up our efforts.”

JADBio’s AutoML platform enables bioinformaticians, oncologists, virologists, data analysts, and other life-scientists to build machine learning models with no coding needed on their part. Its platform is intuitive and easy to use, permitting anyone to upload their data securely, train, and develop a model in a matter of minutes, using highly sophisticated algorithms. JADBio can analyze small sample sizes or vast feature sets, focusing on feature selection and interpretation of the predictive model. Its survival analysis functionality helps clinicians predict life expectancy, cancer metastasis and solve any time-to-event prediction problem. The platform comes with an array of reports and visual graphs to help interpret the model.

About JADBio
Founded in 2019, JADBio was created by academics based in Crete, Greece, with years of research and publications in their background. The company offices are based in Crete, Greece, with satellite offices in Denmark and Los Angeles, CA.


Popi Paraschaki
Digital Giraffes
Visit us on social media:

Source: EIN Presswire


CLEARED4 provides a platform for COVID-19 testing and vaccine status management to more than 1M students across the U.S.

Our flexible platform supports the important testing and vaccine management protocols that will be crucial in keeping the schools open during this educational year.”

— Dr. Soumi Eachempati, CEO of CLEARED4

NEW YORK, NEW YORK, UNITED STATES, September 16, 2021 /EINPresswire.com/ — CLEARED4, the nation’s largest and most trusted HIPAA-compliant business continuity platform, announced today its work with 20+ Illinois-based colleges to provide fast solutions for campus reopenings, including daily health screening, COVID-19 test scheduling, result tracking, vaccine tracking and campus access management. Colleges partnered with CLEARED4 include Elgin Community College, Harper College, McHenry County College, Triton College and Waubonsee Community College.

Across the country, CLEARED4 supports school systems, colleges and universities, teaching more than 1 million students. In recent weeks, CLEARED4 has added dozens of schools in California, which include Los Angeles City College District, El Camino College and San Diego City Colleges, and continues to support operations in New York State schools and universities, including the City University of New York, LIM College and The School of Visual Arts.

“CLEARED4 is extremely proud to partner with so many terrific institutions that need options for monitoring health and complying with the new mandates designed for these challenging times,” said Dr. Soumi Eachempati, CEO of CLEARED4. “Our flexible platform supports the important testing and vaccine management protocols that will be crucial in keeping the schools open during this educational year.”

CLEARED4 is a turnkey platform—used either as a frictionless, standalone experience or as a seamless integrated product in the app of any client—that enables a user’s COVID-19 health status to be connected to any form of access control in real-time such as venue apps or specific employer tools. The flexible solution enables partners to pick any combination of COVID-19 symptom checking, test results and vaccination data to trigger access to an entire location such as a venue or a classroom or a specific zone within that location, using any form of unique identifier, including custom QR codes, government IDs, membership cards, building access cards, wearables and facial recognition.

For more information visit CLEARED4.org.

CLEARED4 is the most trusted health validation platform for COVID-19 and infectious disease safety available today, helping organizations future-proof their operations. The platform enables its clients and users to return safely and confidently to businesses, schools and stadiums, globally. CLEARED4 captures, validates and matches user’s information to real-time health data including health surveys, temperature screening, integrated COVID-19 test results and vaccination status. All this information is then synchronized with third-party systems like door access, digital displays and other control systems. CLEARED4 also supports real-time communication via its HIPAA/FERPA-compliant platform to enterprise IT systems and partner apps. CLEARED4 automates complex health-related administrative tasks with consistent delivery of its fully interoperable and configurable platform that is quick to deploy, needing no additional software development.

CLEARED4 is helping the world reopen and stay open by issuing 10+ million safe access passes per month. CLEARED4 has been retained by organizations proactively protecting their workforce, students, visitors and fans. A partial list of CLEARED4 clients in the U.S. include corporations like Netflix, Sun Chemical, Middlesex Savings Bank, law firms, hedge funds, retail shops, venues such as Madison Square Garden, Yankee Stadium, SoFI Stadium, AT&T Stadium, and educational institutions such as CUNY, El Camino College, School of Visual Arts and Manhasset School District.

Kaitlyn Kurosky
High10 Media

Source: EIN Presswire

AnalyticsIQ Announces Data Integration Partnership with Snowflake

Leading predictive marketing & analytics provider, AnalyticsIQ, can provide Snowflake users with B2C, B2B & custom audience data for analytics and modeling

By joining our marketplace, Snowflake customers will be able to take advantage of our ‘try before you buy’ capabilities so they can evaluate data, including AnalyticsIQ’s.”

— Adrian Bolosan, Snowflake

ATLANTA, GA, UNITED STATES, September 16, 2021 /EINPresswire.com/ — AnalyticsIQ, the leading provider of predictive marketing data, today announced an expanded relationship with Snowflake, the Data Cloud company. AnalyticsIQ will now make its B2C and B2B data available through the Snowflake Data Marketplace. Through this integration, organizations of all sizes and across all industries will have access to thousands of AnalyticsIQ’s powerful, predictive data points. Snowflake users can tap into the power of this data for first-party audience enrichment, custom analytics, predictive modeling, digital targeting, and measurement.

“Our data is incredibly valuable. But what’s wonderful about our integration with Snowflake and the data collaboration capabilities they offer users is that organizations aren’t handcuffed to a single data source,” says Margo Hock, VP of Strategic Partnerships at AnalyticsIQ. “Snowflake Data Marketplace makes it simple for users to not only access the specified data AnalyticsIQ data points they need, but they can easily blend together additional niche data sources and connect it to their own first-party data,” adds Hock.

Snowflake’s approach to managing large amounts of data on a single, integrated platform means that brands who wish to use AnalyticsIQ’s data will be able to access the data offline, online, and even through tokenization partners with ease. Users will experience a streamlined purchasing process and recognize cost-savings through seamless, scalable data storage. As part of AnalyticsIQ's participation in the Snowflake Data Marketplace, companies can also work directly with AnalyticsIQ to develop custom data assets and audiences.

“We are thrilled to have AnalyticsIQ join the Snowflake Data Marketplace. Our company is committed to helping data consumers access the best of the best data providers,” shares Snowflake Industry Principal for Media & Entertainment, Adrian Bolosan. “By joining our marketplace, Snowflake customers will be able to take advantage of our ‘try before you buy’ capabilities so they can evaluate data, including AnalyticsIQ’s, and then seamlessly upgrade to the full dataset when they’re ready,” states Bolosan.

For more information about AnalyticsIQ’s B2C and B2B data available within the Snowflake Data Marketplace, visit https://analytics-iq.com.

About AnalyticsIQ
AnalyticsIQ is a leading predictive analytics and consumer and business marketing data innovator. As the first company to consistently combine cognitive psychology with data science, we help marketers better understand why and how consumers make decisions. Our accurate and comprehensive PeopleCore consumer database provides unrivaled insights to advertisers, agencies, and technology providers. For B2B marketers, the BusinessCore database delivers rich insights on both businesses and individual professionals. Headquartered in Atlanta, AnalyticsIQ’s team of data analysts, scientists, and cognitive psychologists have over 100 years of collective analytical experience and expertise. For more information, visit https://analytics-iq.com/.

Travis Meeks
+1 888-612-4309
email us here

Source: EIN Presswire

CRISPR QC Company COBO Technologies Selected for Prestigious US Accelerator Program

Quality Control Genome Editing

Quality Control Genome Editing

Promising CRISPR QC service provider selected among hundreds of startups

In recent months, we have seen several US-based startups in the same segment with successful funding rounds, so we are very confident that this seed program will help us to secure funding”

— CEO and co-founder, Jens-Ole Bock

COPENHAGEN , DENMARK, September 16, 2021 /EINPresswire.com/ — COBO Technologies, a European start-up company specialised in CRISPR QC services and products, is pleased to announce that it has been selected by the successful US Accelerator, Newchip™.

This intense funding accelerator program is a unique opportunity for COBO Technologies to be part of a vibrant start-up community, to learn from a team of very experienced mentors, and to further expand the investor relation network to secure both the upcoming seed round and future funding rounds.

COBO Technologies also announced earlier this week that it has entered a strategic partnership with the Danish CRO BioXpedia to develop new CRISPR QC solutions for clinical applications.

“The timing is perfect for COBO to enter into this US Accelerator Program and open up a seed round targeting the US investor environment. In recent months, we have seen several US-based startups in the same segment with successful funding rounds, so we are very confident that this seed program will help us to secure seed funding this year and also build the important investor relation network for future series and further expansion into the US market”, says COBO Technologies CEO and co-founder, Jens-Ole Bock.

About COBO Technologies

COBO Technologies is a fast-growing CRO specialised in services and products for quality control of gene-editing applications in research and pre-clinical fields. Today, the company supports customers globally with detailed DNA on- and off-target analysis and proteome profiling of cells, plants or animals modified with gene-editing tools such as CRISPR, ZFNs, Meganucleases and TALENs.

COBO Technologies also founded CRISPR Medicine News in 2019. CRISPR Medicine News is a rapidly-growing news media with a global readership and a network of world-class scientists and industry professionals from the therapeutic gene-editing field.

About Newchip

Newchip Accelerator is a remote, global startup accelerator program. Since 2019, Newchip has launched twelve unique cohorts per year into one of its three programs: Pre-Seed, Seed, or Series A. Qualified startups are interviewed and accepted on a rolling basis. The startups participate in a six month, remote program that comprises founders from over 35 countries. During the program, startup founders work closely with mentors and advisors, engage in mastermind sessions and leverage a vast partner network to prepare them to raise investment capital from angel investors, venture capital, and/or equity crowdfunding. At the end of the program, the startups present their companies to curated investor groups from around the world. The Newchip Accelerator portfolio is valued at over $5 billion, and includes more than 750 graduates that have collectively raised over $150 million in funding.

Jens-Ole Bock
COBO Technologies Aps
+45 24 20 72 21

Source: EIN Presswire